Stock comparison
Edwards Lifesciences
Haemonetics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
EW
Edwards Lifesciences
Market cap
$49.39B
Sector
Healthcare
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
Overall winner
Edwards Lifesciences EW
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | EW | HAE | Winner |
|---|---|---|---|
| Warren Buffett | 61C | 70B | HAE |
| Benjamin Graham | 89A | 85A | EW |
| Philip Fisher | 62C | 60C | EW |
| Peter Lynch | 26F | 54C | HAE |
| Joel Greenblatt | 54C | 31F | EW |
| Charlie Munger | 71C | 54D | EW |
| Terry Smith | 70B | 55D | EW |
Side-by-side metrics
| Metric | EW | HAE |
|---|---|---|
| Market cap | $49.39B | $2.98B |
| P/E (TTM) | 43.2x | 24.8x |
| EV/EBIT | 27.6x | 14.1x |
| ROIC (TTM) | 12.06% | 8.37% |
| Gross margin | 78.01% | 55.74% |
| Net margin | 17.34% | 7.29% |
| Revenue CAGR 5y | 3.77% | 7.65% |
| EPS CAGR 5y | -6.52% | 24.62% |
| Debt / Equity | 0.1x | 1.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
EW leads on
- Debt / Equity0.1xvs 1.5x+96%
- Market cap$49.39Bvs $2.98B+94%
- Net margin17.34%vs 7.29%+58%
- ROIC (TTM)12.06%vs 8.37%+31%
HAE leads on
- EPS CAGR 5y24.62%vs -6.52%+126%
- Revenue CAGR 5y7.65%vs 3.77%+51%
- EV/EBIT14.1xvs 27.6x+49%
- P/E (TTM)24.8xvs 43.2x+43%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.